U.S. markets closed

Global Blood Therapeutics, Inc. (GBT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
28.99+1.26 (+4.54%)
At close: 04:00PM EST
29.60 +0.61 (+2.10%)
After hours: 06:31PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close27.73
Bid27.30 x 1200
Ask29.55 x 1000
Day's Range27.14 - 29.13
52 Week Range24.61 - 52.49
Avg. Volume1,554,007
Market Cap1.868B
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-4.45
Earnings DateFeb 22, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est69.05
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GBT

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Global Blood Therapeutics, Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features our annual pharmaceutical pipeline, a fresh look at Barry Callebaut's chocolate operation, the buzz around RingCentral, and SAP, Subsea 7, and Just Eat Takeaway.
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    Oxbryta® (voxelotor) Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United States

    SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced Oxbryta® (voxelotor) tablets for oral suspension, a new dispersible, once-daily tablet dosage form recently approved by the U.S. Food and Drug Administration (FDA), is now available through GBT’s specialty pharmacy partner network in the United States. On December 17, 2021, the FDA approved Oxbryta (voxelotor) tablets for the treatment of sickle cell disease (SCD) in

  • TipRanks

    Oppenheimer Bullish on These 2 Stocks for 70% Upside (Or More)

    The holidays are behind us, the New Year is getting into full swing, and that means it’s time to figure out, if we can, just where we’re headed in 2022. Last year saw strong gains in the stock markets; the S&P 500 grew 29%, far above the 7% to 8% annual average. The big question for investors is, will the markets keep up this blistering pace? The general consensus is, it won’t – although that doesn’t mean we’re in for a bad year. John Stoltzfus, chief investment strategist with Oppenheimer, note

  • GlobeNewswire

    GBT Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on January 1, 2022, the compensation committee of GBT’s board of directors granted 10 new employees options to purchase an aggregate of 15,225 shares of the company’s common stock with a per share exercise price of $29.27 and restricted stock units for an aggregate of 41,830 shares of the company’s common stock. These awards were made under GBT’s Amended and Res